Unlocking Success from
Research to Patient
When it is critical to understand genomic changes, we offer direct visualization of both intended and unintended modifications through our custom karyotyping services and KromaTiD’s innovative directional Genomic Hybridization (dGH™) technology. Our novel structural genomic integrity analysis gives you the data to help de-risk and accelerate your therapy programs with confidence, allowing you to deliver life-changing therapies to patients as soon as possible.
R&D
Structural Variant Baseline
Vector or Nuclease Comparison
Edit Modality
DNA Damage Assessment
Delivery Optimization
Pre-IND
Donor Qualification
- Baseline structural variance
Cell Therapy Pipeline Development
- Donor qualification
- Batch to batch variability
- Editing optimization
- Single Cell transgene distribution
Clinical
Engineering Batch Expansion
- Performance variability
- Stability
Custom Reporting
Transgene Mapping
Structural Variation Assessment
Commercial
Our commitment to continuous improvement and innovation keeps us at the forefront of single-cell structural genomic analysis, meeting the evolving requirements for research, development, and gene therapy product approvals.
Unmatched Quality Control
KromaTiD’s customized assay development and testing services are tailored to visualize structural variants in chromosomes, advancing life-saving cell and gene therapies throughout their product cycle.
Optimize Your
Editing Approach
Visualize the performance of your genome editing approach against other editing mechanisms with comprehensive and comparative data.
IND Enabling
Packages
We provide robust data and customized reporting for successful IND submissions.